Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan 18:19:571-608.
doi: 10.2147/IJN.S442877. eCollection 2024.

Biomimetic Nano-Drug Delivery System: An Emerging Platform for Promoting Tumor Treatment

Xiujuan Han #  1   2 , Chunai Gong #  3 , Qingru Yang  1   2 , Kaile Zheng  1 , Zhuo Wang  1   2 , Wei Zhang  4
Affiliations
Review

Biomimetic Nano-Drug Delivery System: An Emerging Platform for Promoting Tumor Treatment

Xiujuan Han et al. Int J Nanomedicine. .

Abstract

With the development of nanotechnology, nanoparticles (NPs) have shown broad prospects as drug delivery vehicles. However, they exhibit certain limitations, including low biocompatibility, poor physiological stability, rapid clearance from the body, and nonspecific targeting, which have hampered their clinical application. Therefore, the development of novel drug delivery systems with improved biocompatibility and high target specificity remains a major challenge. In recent years, biofilm mediated biomimetic nano-drug delivery system (BNDDS) has become a research hotspot focus in the field of life sciences. This new biomimetic platform uses bio-nanotechnology to encapsulate synthetic NPswithin biomimetic membrane, organically integrating the low immunogenicity, low toxicity, high tumor targeting, good biocompatibility of the biofilm with the adjustability and versatility of the nanocarrier, and shows promising applications in the field of precision tumor therapy. In this review, we systematically summarize the new progress in BNDDS used for optimizing drug delivery, providing a theoretical reference for optimizing drug delivery and designing safe and efficient treatment strategies to improve tumor treatment outcomes.

Keywords: cell membrane; nanoparticles; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Network diagram illustrating keyword co-occurrences on biomimetic NPs, CM, nano-drug delivery, targeted therapy, tumor treatment.
Figure 2
Figure 2
Biomimetic membrane coated nanoparticles for cancer therapy.
Figure 3
Figure 3
Preparation and application of RBCM-NPs in tumor treatment. (A) Schematic diagram of RBCM-NPs in gene therapy. (B) Design of RBC-NPs that mimic different stages of natural erythrocytes. (C) Schematic diagram of RBCM-NPs in immunotherapy.
Figure 4
Figure 4
Schematic diagram of modified RBCM-NPs for targeted drug delivery.
Figure 5
Figure 5
Schematic diagram of PLTM-NPs for boosting cuproptosis to inhibit breast cancer metastasis and rechallenge.
Figure 6
Figure 6
Schematic diagram the (A) preparation and (B) in vivo primary tumor and lung metastatic site targeted therapy of modified PLTM-NPs.
Figure 7
Figure 7
Schematic of the (A) preparation of CCM-NP and (B and C) discussion on the mechanism of predicting TNBC tumor treatment efficacy using shear wave elastography.
Figure 8
Figure 8
Application in targeted magnetic hyperthermia of the novel shape-anisotropic magnetic core−shell−shell NPs.
Figure 9
Figure 9
Schematic diagram of (a) the preparation of chimeric antigen receptor (CAR)-neutrophil-NPs using genetically engineered human pluripotent stem cells and (b) the mechanism of its roles for glioblastoma chemo-immunotherapy.
Figure 10
Figure 10
Schematic diagram of MM-NPs in situ bioluminescence-driven optogenetic therapy.
Figure 11
Figure 11
Schematic diagram of NEM-NPs for photothermal-induced tumor immunotherapy by triggering pyroptosis.
Figure 12
Figure 12
Schematic diagram of DCM-NPs activate immunotherapy through direct or indirect pathways.
Figure 13
Figure 13
Preparation and application of T-CM-camouflaged NPs (TCM-NPs) in tumor treatment.
Figure 14
Figure 14
Schematic diagram of NKCM-NPs in photodynamic therapy combined with chemoimmunotherapy.
Figure 15
Figure 15
Schematic diagram of BM-NPs in photothermal therapy collaborative immunotherapy. Reproduced, with permission.
Figure 16
Figure 16
Schematic diagram of the modular nanovaccine based on rapidly self-assembling OMVs. (a) Schematic of Avidin-based vaccine antigen crosslinking (AvidVax) technology. (b) Genetic architecture of synthetic antigen-binding protein (SNAP) constructs tested.
Figure 17
Figure 17
Schematic diagram of exosomes-Golgi apparatus HCM-NPs in tumor treatment.
Figure 18
Figure 18
Schematic diagram of (a) the composition of hybrid cell membrane nanovesicles (hNVs) and (b) the mechanism by which hnv effectively enhances the immune response of macrophages.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660 - DOI - PubMed
    1. Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol. 2020;21(7):e342–e349. doi:10.1016/S1470-2045(20)30073-5 - DOI - PubMed
    1. Chen HY, Deng J, Wang Y, Wu CQ, Li X, Dai HW. Hybrid cell membrane-coated nanoparticles: a multifunctional biomimetic platform for cancer diagnosis and therapy. Acta Biomater. 2020;112:1–13. doi:10.1016/j.actbio.2020.05.028 - DOI - PubMed
    1. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124.doi:10.1038/s41573-020-0090-8 - DOI - PMC - PubMed
    1. Su H, Wang Y, Liu S, et al. Emerging transporter-targeted nanoparticulate drug delivery systems. Acta Pharm Sin B. 2019;9(1):49–58. doi:10.1016/j.apsb.2018.10.005 - DOI - PMC - PubMed

Substances

LinkOut - more resources